Randomized placebo-controlled trial of metronidazole 1% cream with sunscreen SPF 15 in treatment of rosacea

J. K L Tan, C. Girard, Alfons Krol, H. E. Murray, K. A. Papp, Y. Poulin, D. A. Chin, D. Jeandupeux

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Rosacea is a photoaggravated dermatosis responsive to treatment with topical and oral antibiotics. A formulation combining metronidazole 1% cream with sunscreen SPF 15 was developed for the treatment of rosacea. Objective: The objective of this study was to determine the safety and efficacy of a formulation combining metronidazole 1% cream with sunscreen SPF 15 in the treatment of moderate to severe rosacea. Methods: One hundred and twenty patients with moderate to severe rosacea were enrolled for a randomized, placebo-controlled (vehicle containing sunscreen with SPF 15), double-blind study. Study cream was applied twice daily to the entire face over a 12-week period. Results: Treatment with metronidazole 1% cream with sunscreen SPF 15 resulted in significant improvement (p <0.05) in inflammatory lesion count, erythema and telangiectasiae scores, and investigator and patient global assessment scores compared with baseline and placebo. Adverse reactions related to study medication were typically mild, occurred at the site of application, and were reversible. There was no difference between the safety profiles of metronidazole 1% cream with sunscreen SPF 15 and placebo. Conclusions: The combined topical formulation of metronidazole 1% cream with sunscreen SPF 15 was an effective, well-tolerated topical agent for the treatment of moderate to severe rosacea.

Original languageEnglish (US)
Pages (from-to)529-534
Number of pages6
JournalJournal of Cutaneous Medicine and Surgery
Volume6
Issue number6
DOIs
StatePublished - Nov 2002
Externally publishedYes

Fingerprint

Rosacea
Sunscreening Agents
Metronidazole
Randomized Controlled Trials
Placebos
Therapeutics
Safety
Erythema
Double-Blind Method
Skin Diseases
Research Personnel
Anti-Bacterial Agents

ASJC Scopus subject areas

  • Dermatology
  • Surgery

Cite this

Randomized placebo-controlled trial of metronidazole 1% cream with sunscreen SPF 15 in treatment of rosacea. / Tan, J. K L; Girard, C.; Krol, Alfons; Murray, H. E.; Papp, K. A.; Poulin, Y.; Chin, D. A.; Jeandupeux, D.

In: Journal of Cutaneous Medicine and Surgery, Vol. 6, No. 6, 11.2002, p. 529-534.

Research output: Contribution to journalArticle

Tan, J. K L ; Girard, C. ; Krol, Alfons ; Murray, H. E. ; Papp, K. A. ; Poulin, Y. ; Chin, D. A. ; Jeandupeux, D. / Randomized placebo-controlled trial of metronidazole 1% cream with sunscreen SPF 15 in treatment of rosacea. In: Journal of Cutaneous Medicine and Surgery. 2002 ; Vol. 6, No. 6. pp. 529-534.
@article{9caa591cad56485bb1231bb068e625db,
title = "Randomized placebo-controlled trial of metronidazole 1{\%} cream with sunscreen SPF 15 in treatment of rosacea",
abstract = "Background: Rosacea is a photoaggravated dermatosis responsive to treatment with topical and oral antibiotics. A formulation combining metronidazole 1{\%} cream with sunscreen SPF 15 was developed for the treatment of rosacea. Objective: The objective of this study was to determine the safety and efficacy of a formulation combining metronidazole 1{\%} cream with sunscreen SPF 15 in the treatment of moderate to severe rosacea. Methods: One hundred and twenty patients with moderate to severe rosacea were enrolled for a randomized, placebo-controlled (vehicle containing sunscreen with SPF 15), double-blind study. Study cream was applied twice daily to the entire face over a 12-week period. Results: Treatment with metronidazole 1{\%} cream with sunscreen SPF 15 resulted in significant improvement (p <0.05) in inflammatory lesion count, erythema and telangiectasiae scores, and investigator and patient global assessment scores compared with baseline and placebo. Adverse reactions related to study medication were typically mild, occurred at the site of application, and were reversible. There was no difference between the safety profiles of metronidazole 1{\%} cream with sunscreen SPF 15 and placebo. Conclusions: The combined topical formulation of metronidazole 1{\%} cream with sunscreen SPF 15 was an effective, well-tolerated topical agent for the treatment of moderate to severe rosacea.",
author = "Tan, {J. K L} and C. Girard and Alfons Krol and Murray, {H. E.} and Papp, {K. A.} and Y. Poulin and Chin, {D. A.} and D. Jeandupeux",
year = "2002",
month = "11",
doi = "10.1007/s10227-001-0144-4",
language = "English (US)",
volume = "6",
pages = "529--534",
journal = "Journal of Cutaneous Medicine and Surgery",
issn = "1203-4754",
publisher = "Decker Publishing",
number = "6",

}

TY - JOUR

T1 - Randomized placebo-controlled trial of metronidazole 1% cream with sunscreen SPF 15 in treatment of rosacea

AU - Tan, J. K L

AU - Girard, C.

AU - Krol, Alfons

AU - Murray, H. E.

AU - Papp, K. A.

AU - Poulin, Y.

AU - Chin, D. A.

AU - Jeandupeux, D.

PY - 2002/11

Y1 - 2002/11

N2 - Background: Rosacea is a photoaggravated dermatosis responsive to treatment with topical and oral antibiotics. A formulation combining metronidazole 1% cream with sunscreen SPF 15 was developed for the treatment of rosacea. Objective: The objective of this study was to determine the safety and efficacy of a formulation combining metronidazole 1% cream with sunscreen SPF 15 in the treatment of moderate to severe rosacea. Methods: One hundred and twenty patients with moderate to severe rosacea were enrolled for a randomized, placebo-controlled (vehicle containing sunscreen with SPF 15), double-blind study. Study cream was applied twice daily to the entire face over a 12-week period. Results: Treatment with metronidazole 1% cream with sunscreen SPF 15 resulted in significant improvement (p <0.05) in inflammatory lesion count, erythema and telangiectasiae scores, and investigator and patient global assessment scores compared with baseline and placebo. Adverse reactions related to study medication were typically mild, occurred at the site of application, and were reversible. There was no difference between the safety profiles of metronidazole 1% cream with sunscreen SPF 15 and placebo. Conclusions: The combined topical formulation of metronidazole 1% cream with sunscreen SPF 15 was an effective, well-tolerated topical agent for the treatment of moderate to severe rosacea.

AB - Background: Rosacea is a photoaggravated dermatosis responsive to treatment with topical and oral antibiotics. A formulation combining metronidazole 1% cream with sunscreen SPF 15 was developed for the treatment of rosacea. Objective: The objective of this study was to determine the safety and efficacy of a formulation combining metronidazole 1% cream with sunscreen SPF 15 in the treatment of moderate to severe rosacea. Methods: One hundred and twenty patients with moderate to severe rosacea were enrolled for a randomized, placebo-controlled (vehicle containing sunscreen with SPF 15), double-blind study. Study cream was applied twice daily to the entire face over a 12-week period. Results: Treatment with metronidazole 1% cream with sunscreen SPF 15 resulted in significant improvement (p <0.05) in inflammatory lesion count, erythema and telangiectasiae scores, and investigator and patient global assessment scores compared with baseline and placebo. Adverse reactions related to study medication were typically mild, occurred at the site of application, and were reversible. There was no difference between the safety profiles of metronidazole 1% cream with sunscreen SPF 15 and placebo. Conclusions: The combined topical formulation of metronidazole 1% cream with sunscreen SPF 15 was an effective, well-tolerated topical agent for the treatment of moderate to severe rosacea.

UR - http://www.scopus.com/inward/record.url?scp=0036873549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036873549&partnerID=8YFLogxK

U2 - 10.1007/s10227-001-0144-4

DO - 10.1007/s10227-001-0144-4

M3 - Article

C2 - 12001006

AN - SCOPUS:0036873549

VL - 6

SP - 529

EP - 534

JO - Journal of Cutaneous Medicine and Surgery

JF - Journal of Cutaneous Medicine and Surgery

SN - 1203-4754

IS - 6

ER -